ArticleBMC public health2025
Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world registry data from an Australian population.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCulturally and/or linguistically diverse (CALD) patients have unique health needs and may face multiple barriers when accessing healthcare. This study explored the association between of CALD status on treatment received and outcomes for patients with pancreatic cancer.
methodsData were extracted from the multi-site PURPLE Pancreatic cancer Translational Registry between January 2016 and April 2023. Registry data was supplemented by country of birth and preferred language data from linkage with hospital administrative datasets. CALD status was defined by being born overseas in a non-main English-speaking country and/or having a preferred language other than English. Descriptive statistics were used to analyse demographic data. Survival analysis was conducted using Kaplan-Meier estimates to generate survival curves, with comparisons assessed via the log-rank test. Moreover, univariable and multivariable Cox proportional hazards regression were employed.
resultsOf 1796 patients with pancreatic cancer enrolled at seven participating institutions, 1451 (80.8%) had their CALD status determined; with 661 (46%) identified as CALD. The CALD population were older (median age 72 vs. 68 years; P < 0.001), with a worse performance status (Eastern Cooperative Oncology Group score > 1: 20 vs. 13%, P = 0.004) and a greater number of comorbidities (Charlson Comorbidity Index > 3: 55 vs. 43%, P < 0.001). The use of neoadjuvant therapy in resectable/borderline resectable disease was similar. However, fewer CALD patients proceeded to curative-intent surgery following neoadjuvant therapy (30% vs. 51%, P = 0.041). In the metastatic setting, a higher proportion of CALD patients were offered best supportive care (50% vs. 41%; P = 0.021). Overall, there were no significant differences identified in the progression-free, recurrence-free or overall survival for CALD patients with pancreatic cancer across all stages of disease.
conclusionsCALD status was associated with multiple adverse prognostic factors (age, PS, comorbidities), which likely impacted differences in treatment received and challenges analysis of the independent impact of CALD status on outcomes. Notably, however, there were no striking differences by CALD status in treatment delivered or survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.